Intrinsic Imaging Awarded Large Five Year Multi-Center Clinical Trial for Metastatic Colorectal Cancer

Share Article

Intrinsic Imaging has been awarded a large five year multi-center clinical trial for metastatic colorectal cancer. Intrinsic Imaging will provide imaging core lab services to manage the entire acquisition, transfer and processing of medical images from hundreds of patients from over 40 investigator sites. Intrinsic Imaging will also provide its team of oncology subspecialized radiologists for RECIST interpretation of many thousands of medical images over the duration of the trial.

"Intrinsic Imaging team of more than sixty board certified radiologists has decades of experience. Our imaging technology and processes enable the robustness and scalability needed for this trial," said Todd Joron, President & COO

Intrinsic Imaging LLC, an ISO 9001:2008 compliant medical imaging core lab providing complete image management and radiological review services to global pharmaceutical, biotechnology and medical device organizations, announces today that it was recently awarded a large multi-center clinical trial related to the treatment of metastatic colorectal cancer.

Over the 5 year duration of this clinical trial, Intrinsic Imaging will provide imaging core lab services to manage the entire acquisition, transfer and processing of medical images from hundreds of patients from over 40 investigator sites. Intrinsic Imaging will also provide its team of oncology subspecialized radiologists for RECIST interpretation of many thousands of medical images over the duration of the trial.

“Intrinsic Imaging radiologists interpret hundreds of thousands of cancer related radiologic exams annually and are experts in the detailed assessment of colorectal tumor burden.” said Neal Dalrymple, MD., Medical Director, Gastrointestinal and Genitourinary Radiology. “We are looking forward to contributing our expertise in this therapeutic area and to working closely with the Sponsor on this important clinical trial.”

The study of colorectal cancer is an important one. The World Health Organization has recently projected that cancer would become the leading cause of death globally; surpassing heart disease and stroke, and that by 2030 the number of deaths caused by cancer would grow to 12 million per year. More specifically, according to the American Cancer Society, colorectal cancer is now the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and women.

In addition to trial management and evaluations related to colon cancer, Intrinsic Imaging is able to guide the performance and radiographic interpretation of the entire digestive tract, including the pharynx, esophagus, stomach, duodenum, small intestine, colon and biliary system as well as all accessory organs to the alimentary canal.

“We are pleased to have been awarded this large colorectal cancer trial. Our team of more than sixty board certified radiologists has decades of experience in this field and our imaging technology and processes enable the robustness and scalability needed for this magnitude and duration of a trial.” said Todd A. Joron, BSc. MBA, President & COO, Intrinsic Imaging.

About Intrinsic Imaging LLC
Located in San Antonio, TX and Boston, MA, Intrinsic is an ISO 9001:2008 compliant medical imaging core lab providing complete image management and radiological review services to global pharmaceutical, biotechnology and medical device organizations. With its team of more than sixty sub-specialized, board-certified radiologists, and through its use of advanced medical imaging technology, Intrinsic Imaging experienced clinical trial team provides sponsors with comprehensive imaging core lab services across all therapeutic areas including expert radiologist consultation, protocol design and image charter development, investigator site qualification and training, as well as image acquisition, processing, analysis and data management. For more information, please visit http://www.IntrinsicCRO.com.

RECIST - Response Evaluation Criteria In Solid Tumors

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Todd Joron
Visit website